Most of what our radar surfaces is ordinary organic chemistry — small molecules and scaffolds, the everyday matter of drug discovery. So it stands out when the list that's climbing starts to include radioactive isotopes: gallium-68, lutetium, zirconium-89, and ligands built to bind PSMA. It's a small cluster. It's also a telling one.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
These aren't drugs in the usual sense
They're two halves of a strategy called theranostics. The same targeting molecule — aimed at a marker like PSMA on prostate cancer, or FAP, which appears across many solid tumors — is paired with one isotope to image the disease and another to treat it. See exactly where the cancer is; then deliver radiation precisely there. The diagnostic and the therapeutic are not two separate drugs that share a target; they are, deliberately, one molecule wearing different cargo.
That has a clinical logic a conventional pill cannot match. Before a patient is ever treated, the imaging version confirms the target is present and shows every lesion that carries it — those whose tumors don't light up are spared a therapy that would not have worked, and those who do are mapped in three dimensions first.
The category's breakout is Pluvicto, a lutetium-177 PSMA-targeted therapy that showed a survival benefit in metastatic prostate cancer and won FDA approval, paired with a gallium-68 PSMA imaging companion. [1] It is not alone: Lutathera, another lutetium-177 therapy, is already approved for neuroendocrine tumors. The isotopes in our radar are the chemistry of the next wave — including ligands aimed at FAP, a target present across a wide range of tumors.
Two isotopes, one molecule: the physics
What makes the see-it-then-treat-it playbook work is that the choice of isotope changes what a molecule does without changing where it goes. Hang a positron-emitting isotope on the scaffold and you get an imaging agent; hang a particle-emitting isotope on the identical scaffold and you get a therapy. The targeting is held constant while the radiation physics is swapped.
On the imaging side, gallium-68 and zirconium-89 are positron emitters. Each emitted positron travels a fraction of a millimeter, meets an electron, and annihilates into a pair of photons flying in opposite directions — the coincidence signal a PET scanner turns into a quantitative, three-dimensional picture. Gallium-68 decays in about an hour, which suits a small molecule that clears quickly; zirconium-89 lives for days, long enough to ride along with a slow antibody as it reaches a tumor.
On the therapy side the goal is the opposite: deposit energy, not photons. Lutetium-177 is a beta-emitter, throwing off electrons that travel a couple of millimeters through tissue — enough to irradiate a small cluster of cells around each targeted molecule through a "crossfire" effect, a range well matched to visible tumor deposits. The frontier is alpha-emitters such as actinium-225, which fire much heavier particles over only a few cell-widths but with far greater destructive density — potent against micrometastases and radioresistant disease. Beta reaches farther and hits softer; alpha reaches barely at all and hits like a hammer. Choosing between them is a dosimetry decision about tumor size, location, and the tissue you must protect.
How a radioligand is built
A radioligand is a small kit of parts. There is a targeting vector — a peptide, small molecule, or antibody that finds the marker on the cancer cell; a linker that tunes how the whole construct circulates and clears; and a chelator, a molecular cage, often a macrocycle such as DOTA, whose only job is to grip a metal atom tightly enough that it never falls off in the bloodstream. The radioactive metal — gallium-68, lutetium-177, actinium-225 — is snapped into that cage in the final step.
That architecture is why one scaffold can serve both roles: because the metal sits in a chelator rather than being welded into the drug's backbone, a maker can load an imaging metal or a therapy metal into what is otherwise the same molecule — a "matched pair." It also explains why radiochemistry is unforgiving. The isotope is often married to the cold precursor only hours before the dose goes into a patient, so the chelation must be fast, clean, and near-quantitative on the clock of a decaying nuclide. Purity of the isotope matters as much: "no-carrier-added" lutetium-177, in which essentially every lutetium atom is the radioactive one rather than diluted with non-radioactive lutetium, packs far more activity onto the same targeting molecules — so more of the vectors carry a payload and less cold competitor blocks the target.
Where the isotopes come from
Radioactive metals are not made in a chemistry lab; they come from nuclear infrastructure, and that infrastructure splits along the physics. Neutron-rich therapy isotopes like lutetium-177 come from reactors, where target material is bombarded with neutrons — for the no-carrier-added grade, by irradiating ytterbium and separating out the lutetium that grows in. Proton-rich imaging isotopes are produced in different ways: gallium-68 is usually eluted from a tabletop generator right where it's used, while zirconium-89 is cyclotron-made but long-lived enough (days) to ship. The truly short-lived PET isotopes are the ones that must be made within minutes of the scan, which is why many cities keep a cyclotron nearby.
The best-known piece of this plumbing is the generator. Molybdenum-99, a reactor product, decays into technetium-99m — the workhorse of conventional nuclear-medicine imaging — and hospitals keep a shielded generator to "milk" fresh technetium from it each day. Gallium-68 has a similar arrangement, eluted on demand from a longer-lived germanium parent. The generator is the trick that lets a clinic use an isotope that would never survive shipment on its own.
The supply is thinnest where the science is newest. Actinium-225, the alpha-emitter everyone is excited about, has historically been extracted in tiny quantities from the decay of aging thorium stockpiles, with accelerator-based routes still scaling up; global output has long been a bottleneck. The older workhorses are fragile too: the reactors that make molybdenum-99 are few and aging, and a run of outages once cut the supply of that isotope by about a third in a single year. When one reactor goes dark, there is no warehouse to draw down.
A fast-growing market on a fragile supply
Radioligand therapy is one of the faster-growing corners of oncology — analysts put the market in the low single-digit billions today and rising toward the tens of billions over the coming decade, with lutetium-177 the single largest slice. [2] But the demand curve and the supply curve run on completely different clocks — the defining feature of the field.
Because the product decays, it cannot be stockpiled or shipped the long way around. A therapeutic dose is calibrated to the exact hour it will be injected and manufactured to order; a delayed flight or a missed customs window doesn't spoil the inventory, it deletes it. Production has to be regional and time-critical, with the isotope, the radiolabeling, and the patient appointment choreographed into a window measured in hours to days.
Who has to move when the wave arrives
A rising radioligand does not lift one industry; it pulls on a chain of them at once. Isotope producers — reactor operators, cyclotron networks, and generator makers — sit at the head of it, and their capacity is set years in advance. Radiopharma CDMOs do the radiolabeling and sterile fill-finish under both pharmaceutical GMP and a radioactive-materials license, a rare pairing. Upstream of them, precursor and chelator suppliers provide the cold kits, GMP-grade peptides, and chelation chemistry the isotope is loaded into.
At the far end are the hospital nuclear-medicine networks — the radiopharmacies, hot labs, dosing suites, and trained staff that administer these agents and manage the radioactive waste that follows. Each link has its own lead time and its own choke point, and none can be improvised when a new target suddenly draws demand. That is why an early read on which targets and isotopes are gathering momentum is worth more here than in almost any other part of pharma: the people who must expand a reactor cycle, book cyclotron time, or qualify a new labeling line cannot do it on a quarter's notice.
The caveats — and why the supply chain is the whole game
None of this is frictionless. Reimbursement for radioligand therapy is still maturing, and the economics of an expensive, individually manufactured dose look nothing like a bottle of pills — hospitals must justify the hot-lab investment against throughput they can actually bill. Radiation-handling regulation adds another layer: licensing, shielding, staff dosimetry, and waste disposal are not optional, and they determine how quickly any site can come online. And capacity is the slowest variable of all — reactors and cyclotrons are enormous capital projects with multi-year lead times and a scarce specialist workforce, so supply cannot simply flex to meet a spike in demand.
Which is the whole point. Radiopharma is a completely different commercial proposition from a pill: the isotopes decay, the production is regional and on-demand, and the supply chain — not the molecule alone — is the moat. When you cannot warehouse the product and cannot stand up the capacity overnight, seeing the wave form early — which targets, which isotopes, moving from the science bench toward the clinic — is worth more than almost anywhere else in the industry. A small cluster of isotopes on our radar is, in that light, less a curiosity than a lead indicator for an entire supply chain that has to start building now.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.